News

As per the terms of the agreement, Minophagen is expected to get license for the development and commercialization of Eisai‘s Bexarotene in Japan. However, Eisai is expected to

The double blind, placebo controlled, multi-center clinical study will evaluate the effects of OCA compared with placebo in adult NASH patients. The 72-week study will enroll 280 patients

As per the terms of the agreement, Shionogi is responsible to pay technology access fees and payments to Shionogi for follow-up chemistry for the generation of various, novel

Cinryze is a plasma-derived C1 esterase inhibitor product that has been approved by the US FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with

According to GSK and Valeant, EC has given its approval on the basis of the results from pivotal Phase III studies 1 and 2 and Study 205, a

Under the collaboration agreement, Asterand and 5AM Solutions are expected to share the development costs to build software offering a standardized solution to identify, annotate and distribute human

CTP-499, invented using Concert’s DCE Platform (deuterated chemical entity platform), is a potential first-in-class treatment for chronic kidney disease. It is a deuterium containing new chemical entity which

The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray serves as platform for the development of

The trial was designed to demonstrate survival benefit for patients treated with PHP after 28 days compared to placebo (+ standard care), and at day 60 and day